KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) EBT (2018 - 2025)

Historic EBT for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $28.9 million.

  • BioNTech SE's EBT fell 8343.22% to $28.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$573.6 million, marking a year-over-year decrease of 6853.11%. This contributed to the annual value of -$724.2 million for FY2024, which is 15674.68% down from last year.
  • Per BioNTech SE's latest filing, its EBT stood at $28.9 million for Q3 2025, which was down 8343.22% from -$455.8 million recorded in Q2 2025.
  • Over the past 5 years, BioNTech SE's EBT peaked at $5.6 billion during Q1 2022, and registered a low of -$867.8 million during Q2 2024.
  • Its 5-year average for EBT is $1.6 billion, with a median of $713.6 million in 2023.
  • As far as peak fluctuations go, BioNTech SE's EBT soared by 219983680252.17% in 2021, and later plummeted by 14745.3% in 2024.
  • BioNTech SE's EBT (Quarter) stood at $5.4 billion in 2021, then tumbled by 39.98% to $3.2 billion in 2022, then crashed by 77.95% to $713.6 million in 2023, then crashed by 54.89% to $321.9 million in 2024, then tumbled by 91.03% to $28.9 million in 2025.
  • Its last three reported values are $28.9 million in Q3 2025, -$455.8 million for Q2 2025, and -$468.5 million during Q1 2025.